U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07222969) titled 'A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors' on Oct. 22.
Brief Summary: This clinical trial is an open-label, single-arm, non-randomized, dose-escalation and dose-expansion study targeting subjects with unresectable, advanced, malignant solid tumors who have failed or are unsuitable for standard treatments or refused the existing treatments.
This study is divided into a dose-escalation phase (Phase I) and a dose-expansion phase (Phase II). Phase I (dose escalation) is designed to preliminarily evaluate the safety and tolerability of VIB305 in advanced solid tumors, to determine the natur...